Torqur AG is a clinical-stage biotechnology company focused on the discovery and development of PI3K/mTOR inhibitors for cancer therapy. The company is developing a portfolio of dual PI3K/mTOR compounds, including the candidate bimiralisib (PQR309) formulated for oral and topical use, and is conducting clinical trials in oncology and dermatology indications.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Platform for the discovery and efficient development of innovative anti-cancer therapies focused on the PI3K/mTOR signaling pathway and next-generation agents.
PI3K/mTOR inhibitors
Development of disease-specific mTOR and/or PI3K inhibitors with optimized pharmacokinetic and safety profiles for oncology and dermatology applications.
Bimiralisib (PQR309)
Lead candidate as a dual pan-PI3K and mTOR inhibitor for oral and topical use, investigated in multiple Phase 1/2 studies and additional clinical programs.
Clinical development in oncology and dermatology
Early clinical development and proof-of-concept studies for bimiralisib in various oncology and dermatology indications.
Pipeline development of next-generation PI3K/mTOR inhibitors
Building a portfolio with next-generation PI3K/mTOR inhibitors to expand therapeutic areas in oncology and beyond.
Knowledge
No knowledge articles yet
Once Torqur AG has claimed this profile, we'll publish editorial articles and case studies here together.